Hyaluronic Acid Market Size, Share & Trends Analysis Report By Application (Dermal Fillers, Osteoarthritis, Ophthalmic, Vesicoureteral Reflux), By Region (North America, APAC), And Segment Forecasts, 2021 - 2028

Published: December 2, 2021 |

Grand View Research, Inc. | 154 Pages | Delivery time: 2-10 business days

Price

Description
Table of Contents
List of Tables

Add to Compare

Hyaluronic Acid Market Growth & Trends:

The global hyaluronic acid market size is expected to reach USD 14.4 billion by 2028, expanding at a CAGR of 7.19%, according to a new report by Grand View Research, Inc. Factors, such as increasing concern of population regarding chemicals, desire to get quick and evident results, and shorter recovery time, are high impact rendering drivers for this market. The market is evolving rapidly due to the increasing adoption of aesthetic procedures in developed and developing regions. Increasing the use of hyaluronic acid surfaces in cardiovascular implants, such as stents and vascular grafts, for improving the compatibility coupled with growing awareness about anti-aging products is fueling the growth. The efficacy and evident results of hyaluronic acid-based dermal fillers are attracting consumers.

Furthermore, the COVID-19 pandemic has changed the dynamics of many industries, with movement restrictions, social distancing, and revised practices becoming the "new normal." As the cosmetic industry is gradually resuming its operations, a number of doctors have reported a significant increase in the inquiries for aesthetic surgeries. Moreover, the lockdown has encouraged all professionals to use video-conferencing facilities, which has made people more conscious about their looks. In some cases, it has led people to opt for cosmetic treatments; this is termed as the "Zoom Boom" or the "Zoom effect." Cosmetic surgeons across the world have witnessed a significant increase in the number of patients as a result of the pandemic, particularly in countries, such as the U.S., Australia, and Japan.

The market in Asia Pacific is anticipated to register the fastest CAGR during the forecast period due to the rising geriatric population in China and Japan, which drives demand for anti-aging products and services. Increasing awareness about the applications of hyaluronan and its efficacy also fuels the demand. In addition, stabilizing economies leave the middle-class population with surplus money to spend on these procedures. The European market for orthopedic biomaterials has undergone impressive changes over the last 2 years. The high demand is witnessing increasing price competition owing to new entrants. The WHO recently announced the obesity epidemic in the U.K. and Germany. The relationship between the increasing aging population and obesity is a potential driver for the market in Europe.

Hyaluronic Acid Market Report Highlights:

The osteoarthritis segment held the largest share in 2020 due to increased cases of obesity resulting in osteoarthritis &joint pain, which have boosted the product demand as a treatment

Hyaluronic acid acts as a shock absorber or a cushion and lubricates the joints, thus helping in the proper functioning

There are a number of ophthalmic surgical products that use hyaluronan/hyaluronic acid as an active ingredient. These include Vitrax, Healon, Amivisc Plus, Amvisc, Hylan G-F20, and Opegan

The increasing prevalence of age-related eye diseases, dry eye syndrome, adult-vision impairments, and chronic diseases, such as diabetes, are major factors leading to market growth for the ophthalmic application segment

Growing preference for short-treatment regimens, even though high priced, and high prevalence of target diseases are the key factors driving the market in North America

Product Code: 978-1-68038-333-1

Chapter 1 Methodology and Scope

1.1 Market Segmentation & Scope
- 1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 Gvr's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
- 1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
- 1.6.1 Commodity Flow Analysis
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
- 1.9.1 Objective 1
- 1.9.2 Objective 2
- 1.9.3 Objective 3

Chapter 2 Executive Summary

2.1 Market Outlook
2.2 Segment Outlook
- 2.2.1 Application
- 2.2.2 Region
2.3 Competitive Insights

Chapter 3 Market Variables, Trends, & Scope

3.1 Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.1.2 Related/Ancillary Market Outlook
  - 3.1.2.1 Facial injectable market
  - 3.1.2.2 Knee replacement/implants market
3.2 User Perspective Analysis
- 3.2.1 Consumer Behavior Analysis
- 3.2.2 Market Influencer Analysis
3.3 Market Dynamics
- 3.3.1 Market Driver Analysis
  - 3.3.1.1 Increasing geriatric population
  - 3.3.1.2 Growing awareness for antiaging products
  - 3.3.1.3 High prevalence of target diseases
- 3.3.2 Market Restraint Analysis
  - 3.3.2.1 Associated adverse effects of hyaluronic acid
  - 3.3.2.2 High cost of products and related services
3.4 Business Environment Analysis Tools
- 3.4.1 Pestle Analysis
  - 3.4.1.1 Political & legal landscape
  - 3.4.1.2 Economic & social landscape
  - 3.4.1.3 Technological landscape
- 3.4.2 Porter's Five Forces Analysis
  - 3.4.2.1 Competitive rivalry: HIGH
  - 3.4.2.2 Bargaining power of suppliers: Moderate
  - 3.4.2.3 Bargaining power of buyers: Moderate
  - 3.4.2.4 Threat of new entrants: Moderate
  - 3.4.2.5 Threat of substitutes: Moderate
3.5 Penetration & Growth Prospect Mapping
3.6 Major Deals & Strategic Alliances Analysis
- 3.6.1 Licensing & partnerships, technology collaborations
- 3.6.2 Mergers & Acquisitions
3.7 Impact of COVID-19: Qualitative Analysis

Chapter 4 Hyaluronic Acid Market: Application Analysis

4.1 Hyaluronic Acid Market Share analysis, 2020 & 2028
4.2 Segment Dashboard
4.3 Market Size & Forecasts and Trend Analysis, 2016 to 2028 for the Application
- 4.3.1 Osteoarthritis
  - 4.3.1.1 Osteoarthritis market, 2016 - 2028 (USD Million)
  - 4.3.1.2 Three injection
  - 4.3.1.2.1 Three injection market, 2016 - 2028 (USD Million)
  - 4.3.1.3 Single injection
  - 4.3.1.3.1 Single-injection market, 2016 - 2028 (USD Million)
  - 4.3.1.4 Five injection
  - 4.3.1.4.1 Five injection market, 2016 - 2028 (USD Million)
- 4.3.2 Dermal Fillers
  - 4.3.2.1 Dermal fillers market, 2016 - 2028 (USD Million)
- 4.3.3 Ophthalmic
  - 4.3.3.1 Ophthalmic market, 2016 - 2028 (USD Million)
- 4.3.4 Vesicoureteral Reflux
  - 4.3.4.1 Vesicoureteral reflux market, 2016 - 2028 (USD Million)

Chapter 5 Hyaluronic Acid Market: Regional Analysis

5.1 Regional Market Share Analysis, 2020 & 2028
5.2 Regional Market Snapshot
5.3 Market Size & Forecasts and Trend Analysis, 2020 to 2028
- 5.3.1 North America
  - 5.3.1.1 North America hyaluronic acid market, 2016 - 2028 (USD Million)
  - 5.3.1.2 U.S.
  - 5.3.1.2.1 U.S. hyaluronic acid market, 2016 - 2028 (USD MILLION)
  - 5.3.1.3 Canada
  - 5.3.1.3.1 Canada hyaluronic acid market, 2016 - 2028 (USD Million)
- 5.3.2 Europe
  - 5.3.2.1 Europe hyaluronic acid market, 2016 - 2028 (USD Million)
  - 5.3.2.2 Germany
  - 5.3.2.2.1 Germany hyaluronic acid market, 2016 - 2028 (USD Million)
  - 5.3.2.3 France
  - 5.3.2.3.1 France hyaluronic acid market, 2016 - 2028 (USD Million)
  - 5.3.2.4 Spain
  - 5.3.2.4.1 Spain hyaluronic acid market, 2016 - 2028 (USD Million)
  - 5.3.2.5 U.K.
  - 5.3.2.5.1 U.K. hyaluronic acid market, 2016 - 2028 (USD Million)
  - 5.3.2.6 Italy
  - 5.3.2.6.1 Italy hyaluronic acid market, 2016 - 2028 (USD Million)
- 5.3.3 Asia Pacific
  - 5.3.3.1 Asia Pacific hyaluronic acid market, 2016 - 2028 (USD Million)
  - 5.3.3.2 Japan
  - 5.3.3.2.1 Japan hyaluronic acid market, 2016 - 2028 (USD Million)
  - 5.3.3.3 China
  - 5.3.3.3.1 China hyaluronic acid market, 2016 - 2028 (USD Million)
  - 5.3.3.4 India
  - 5.3.3.4.1 India hyaluronic acid market, 2016 - 2028 (USD Million)
- 5.3.4 Latin America
  - 5.3.4.1 Latin America hyaluronic acid market, 2016 - 2028 (USD Million)
  - 5.3.4.2 Brazil
  - 5.3.4.2.1 Brazil hyaluronic acid market, 2016 - 2028 (USD Million)
  - 5.3.4.3 Mexico
  - 5.3.4.3.1 Mexico hyaluronic acid market, 2016 - 2028 (USD Million)
- 5.3.5 Middle East & Africa
  - 5.3.5.1 MEA hyaluronic acid market, 2016 - 2028 (USD Million)
  - 5.3.5.2 South Africa
  - 5.3.5.2.1 South africa hyaluronic acid market, 2016 - 2028 (USD Million)

Chapter 6 Reimbursement Outlook

6.1 Reimbursement by Product
- 6.1.1 GEL-ONE
- 6.1.2 EUFLEXXA
- 6.1.3 SYNVISC-ONE
- 6.1.4 SUPARTZ
- 6.1.5 HYALGAN
- 6.1.6 MONOVISC
- 6.1.7 ORTHOVISC
- 6.1.8 OTHERS
6.2 Reimbursement by Region
- 6.2.1 U.S.
- 6.2.2 Canada
- 6.2.3 China
- 6.2.4 Japan
- 6.2.5 India
- 6.2.6 Brazil
- 6.2.7 South Africa
- 6.2.8 Europe
  - 6.2.8.1 UK
  - 6.2.8.2 Germany
  - 6.2.8.3 France
  - 6.2.8.4 Italy
  - 6.2.8.5 Spain

Chapter 7 Competitive Analysis

7.1 Recent Developments & Impact Analysis, by Key Market Participants
7.2 Competition Categorization
7.3 Vendor Landscape
- 7.3.1 List Of Key Distributors And Channel Partners
- 7.3.2 Strategy Mapping
  - 7.3.2.1 Launch of new products
  - 7.3.2.2 Geographical expansion
  - 7.3.2.3 Marketing& promotions
7.4 Company Market Position Analysis
- 7.4.1 Company Market Position Analysis
7.5 Company Profiles
- 7.5.1 ALLERGAN
  - 7.5.1.1 Company overview
  - 7.5.1.2 Financial performance
  - 7.5.1.3 Product benchmarking
  - 7.5.1.4 Strategic initiatives
  - 7.5.1.5 SWOT analysis
- 7.5.2 SANOFI
  - 7.5.2.1 Company overview
  - 7.5.2.2 Financial performance
  - 7.5.2.3 Product benchmarking
  - 7.5.2.4 Strategic initiatives
  - 7.5.2.5 SWOT analysis
- 7.5.3 GENZYME CORPORATION
  - 7.5.3.1 Company overview
  - 7.5.3.2 Product benchmarking
- 7.5.4 ANIKA THERAPEUTICS, INC.
  - 7.5.4.1 Company overview
  - 7.5.4.2 Financial performance
  - 7.5.4.3 Product benchmarking
  - 7.5.4.4 Strategic initiatives
  - 7.5.4.5 SWOT analysis
- 7.5.5 SALIX PHARMACUETICALS
  - 7.5.5.1 Company overview
  - 7.5.5.2 Financial performance
  - 7.5.5.3 Product benchmarking
  - 7.5.5.4 Strategic initiatives
  - 7.5.5.5 SWOT analysis
- 7.5.6 SEIKAGAKU CORPORATION
  - 7.5.6.1 Company overview
  - 7.5.6.2 Financial performance
  - 7.5.6.3 Product benchmarking
  - 7.5.6.4 Strategic initiatives
  - 7.5.6.5 SWOT analysis
- 7.5.7 F. HOFFMANN-LA ROCHE AG
  - 7.5.7.1 Company overview
  - 7.5.7.2 Financial performance
  - 7.5.7.5 Product benchmarking
  - 7.5.7.4 SWOT analysis
- 7.5.8 GALDERMA LABORATORIES L.P.
  - 7.5.8.1 Company overview
  - 7.5.8.2 Financial performance
  - 7.5.8.3 Product benchmarking
  - 7.5.8.4 Strategic initiatives
  - 7.5.8.5 SWOT analysis
- 7.5.9 ZIMMER BIOMET
  - 7.5.9.1 Company overview
  - 7.5.9.2 Financial performance
  - 7.5.9.3 Product benchmarking
  - 7.5.9.4 Strategic initiatives
  - 7.5.9.5 SWOT analysis
- 7.5.10 SMITH & NEPHEW PLC
  - 7.5.10.1 Company overview
  - 7.5.10.2 Financial performance
  - 7.5.10.3 Product benchmarking
  - 7.5.10.4 Strategic initiatives
  - 7.5.10.5 SWOT analysis
- 7.5.11 FERRING B.V
  - 7.5.11.1 Company overview
  - 7.5.11.2 Financial performance
  - 7.5.11.3 Product benchmarking
  - 7.5.11.4 Strategic initiatives
- 7.5.12 LIFECORE BIOMEDICAL, LLC
  - 7.5.12.1 Company overview
  - 7.5.12.2 Financial performance
  - 7.5.12.3 Product benchmarking
  - 7.5.12.4 Strategic initiatives
  - 7.5.12.5 SWOT analysis
- 7.5.13 HTL BIOTECHNOLOGY
  - 7.5.13.1 Company overview
  - 7.5.13.2 Financial performance
  - 7.5.13.3 Product benchmarking
  - 7.5.13.4 Strategic initiatives
- 7.5.14 SHISEIDO COMPANY, LIMITED
  - 7.5.14.1 Company overview
  - 7.5.14.2 Financial performance
  - 7.5.14.3 Product benchmarking
  - 7.5.14.4 Strategic initiatives
  - 7.5.14.5 SWOT analysis
- 7.5.15 BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED
  - 7.5.15.1 Company overview
  - 7.5.15.2 Financial Performance
  - 7.5.15.3 Product benchmarking
  - 7.5.15.4 Strategic initiatives
  - 7.5.15.5 SWOT analysis
- 7.5.16 LG LIFE SCIENCES LTD (LG CHEM.)
  - 7.5.16.1 Company overview
  - 7.5.16.2 Financial Performance
  - 7.5.16.3 Product benchmarking
  - 7.5.16.4 Strategic initiatives
  - 7.5.16.5 SWOT analysis
- 7.5.17 MARUHA NICHIRO, INC.
  - 7.5.17.1 Company overview
  - 7.5.17.2 Financial performance
  - 7.5.17.3 Product benchmarking
  - 7.5.17.4 Strategic initiatives
  - 7.5.17.5 SWOT analysis

List of Tables

TABLE 1 North America hyaluronic acid market, by country, 2016 - 2028 (USD Million)
TABLE 2 North America hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 3 U.S. hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 4 Canada hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 5 Europe hyaluronic acid market, by country, 2016 - 2028 (USD Million)
TABLE 6 Europe hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 7 U.K. hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 8 Germany hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 9 France hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 10 Italy hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 11 Spain hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 12 Asia Pacific hyaluronic acid market, by country, 2016 - 2028 (USD Million)
TABLE 13 Asia Pacific hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 14 Japan hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 15 China hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 16 India hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 17 Latin America hyaluronic acid market, by country, 2016 - 2028 (USD Million)
TABLE 18 Latin America hyaluronic acid market by application, 2016 - 2028 (USD Million)
TABLE 19 Brazil hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 20 Mexico hyaluronic acid market by application, 2016 - 2028 (USD Million)
TABLE 21 MEA hyaluronic acid market, by country, 2016 - 2028 (USD Million)
TABLE 22 MEA hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 23 South Africa hyaluronic acid market, by application, 2016 - 2028 (USD Million)
TABLE 24 List of secondary sources
TABLE 25 List of abbreviation
TABLE 26 List of secondary sources
TABLE 27 List of abbreviation
TABLE 28 Cost of viscosupplements- U.S.
TABLE 29 NYS non-coverage details
TABLE 30 HCPCS Code
TABLE 31 Labelling instructions by the FDA
TABLE 32 Distribution and marketing rights of Synvisc